Mandate

Vinge advises Epsilon’s owner Danir in connection with Epsilon’s merger with ÅF

October 18, 2012

Vinge is advising Danir, which is owned by Dan Olofsson, in connection with the merger of Danir’s subsidiary, Epsilon, with ÅF. The merger will be effected through ÅF acquiring all of the shares in Epsilon from Danir. The merger is driven by a strong industrial logic, since ÅF and Epsilon largely share a common culture and complement each other in terms of technical expertise, service offering, customer base and geographical presence. Over the last twelve months, the new ÅF Group would have had annual sales of approximately SEK 7.8 billion.

The consideration consists of an initial purchase price of approximately SEK 1,700 million (enterprise value), consisting partly of SEK 850 million in cash and partly of 5,985,915 newly issued class B shares in ÅF. There will also be an additional purchase price amounting to a maximum of SEK 1,100 million. The completion of the Transaction is conditional upon approval by the relevant competition authorities and approval by the ÅF Extraordinary General Meeting, which will be held on 19 November 2012.

Vinge’s team advising Danir consists of partners Peter Oscarsson, Jesper Ottergren and Pär Remmelid and associate Karolina Tjärnberg Jansson.

Related

Vinge advises Trianon in connection with directed share issue and tender offer for subordinated sustainable capital securities

Vinge advises Fastighets Aktiebolaget Trianon (publ) in connection with a directed share issue of SEK 184 million and a tender offer for outstanding subordinated perpetual floating rate callable sustainable capital securities.
April 19, 2024

Vinge advises Blackstone in connection with its investment in Winthrop Technologies

Vinge, as local Swedish counsel, advised Blackstone Tactical Opportunities and affiliated funds (“Blackstone”) in connection with a strategic partnership with Winthrop Technologies Limited (“Winthrop Technologies”).
April 17, 2024

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of SEK 372 million before transaction costs. Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.
April 16, 2024